Martinez, Carmen, Gayoso, Jorge, Canals, Carmen, Finel, Herve, Peggs, Karl, Dominietto, Alida, Castagna, Luca, Afanasyev, Boris, Robinson, Stephen, Blaise, Didier, Corradini, Paolo, Itala-Remes, Maija, Bermudez, Arancha, Forcade, Edouard, Russo, Domenico, Potter, Michael, McQuaker, Grant, Yakoub-Agha, Ibrahim ORCID: 0000-0003-4524-8782, Scheid, Christof, Bloor, Adrian, Montoto, Silvia ORCID: 0000-0002-3006-9725, Dreger, Peter and Sureda, Anna (2017). Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. J. Clin. Oncol., 35 (30). S. 3425 - 3436. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Full text not available from this repository.

Abstract

Purpose To compare the outcome of patients with Hodgkin lymphoma who received post-transplantation cyclophosphamide-based haploidentical (HAPLO) allogeneic hematopoietic cell transplantation with the outcome of patients who received conventional HLA-matched sibling donor (SIB) and HLA-matched unrelated donor (MUD). Patients and Methods We retrospectively evaluated 709 adult patients with Hodgkin lymphoma who were registered in the European Society for Blood and Marrow Transplantation database who received HAPLO (n = 98), SIB (n = 338), or MUD (n = 273) transplantation. Results Median follow-up of survivors was 29 months. No differences were observed between groups in the incidence of acute graft-versus-host disease (GVHD). HAPLO was associated with a lower risk of chronic GVHD (26%) compared with MUD (41%; P =.04). Cumulative incidence of nonrelapse mortality at 1 year was 17%, 13%, and 21% in HAPLO, SIB, and MUD, respectively, and corresponding 2-year cumulative incidence of relapse or progression was 39%, 49%, and 32%, respectively. On multivariable analysis, relative to SIB, nonrelapse mortality was similar in HAPLO (P =.26) and higher in MUD (P =.003), and risk of relapse was lower in both HAPLO (P =.047) and MUD (P,.001). Two-year overall survival and progression-free survival were 67% and 43% for HAPLO, 71% and 38% for SIB, and 62% and 45% for MUD, respectively. There were no significant differences in overall survival or progression-free survival between HAPLO and SIB or MUD. The rate of the composite end point of extensive chronic GVHD and relapse-free survival was significantly better for HAPLO (40%) compared with SIB (28%; P =.049) and similar to MUD (38%; P =.59). Conclusion Post-transplantation cyclophosphamide-based HAPLO transplantation results in similar survival outcomes compared with SIB and MUD, which confirms its suitability when no conventional donor is available. Our results also suggest that HAPLO results in a lower risk of chronic GVHD than MUD transplantation. (C) 2017 by American Society of Clinical Oncology

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Martinez, CarmenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gayoso, JorgeUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Canals, CarmenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Finel, HerveUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Peggs, KarlUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dominietto, AlidaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Castagna, LucaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Afanasyev, BorisUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Robinson, StephenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Blaise, DidierUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Corradini, PaoloUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Itala-Remes, MaijaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bermudez, AranchaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Forcade, EdouardUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Russo, DomenicoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Potter, MichaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
McQuaker, GrantUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Yakoub-Agha, IbrahimUNSPECIFIEDorcid.org/0000-0003-4524-8782UNSPECIFIED
Scheid, ChristofUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bloor, AdrianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Montoto, SilviaUNSPECIFIEDorcid.org/0000-0002-3006-9725UNSPECIFIED
Dreger, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sureda, AnnaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-214081
DOI: 10.1200/JCO.2017.72.6869
Journal or Publication Title: J. Clin. Oncol.
Volume: 35
Number: 30
Page Range: S. 3425 - 3436
Date: 2017
Publisher: AMER SOC CLINICAL ONCOLOGY
Place of Publication: ALEXANDRIA
ISSN: 1527-7755
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
STEM-CELL TRANSPLANTATION; RELAPSE-FREE SURVIVAL; VERSUS-HOST-DISEASE; HEMATOLOGIC MALIGNANCIES; ALLOGENEIC TRANSPLANTATION; INTENSITY; OUTCOMES; EXPERIENCE; LEUKEMIA; REGIMENMultiple languages
OncologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/21408

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item